Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 3500
Single User License Price INR 241500
Corporate User License Price USD 10500
Corporate User License Price INR 724500
Site License Price USD 7000
Site License Price INR 483000
Request a Quote

Report Title

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Pipeline Review, H2 2017

Quote Request for License Type
License Type Price  
Single User License USD 3500
Site License USD 7000
Enterprise Wide License USD 10500
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Pipeline Review, H2 2017


Quote Request for License Type
License Type Price  
Single User License USD 3500
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Pipeline Review, H2 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Pipeline Review, H2 2017



Executive Summary

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Hepatocyte Growth Factor-Pipeline Review, H2 2017'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor. It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing. In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.

The report 'Hepatocyte Growth Factor-Pipeline Review, H2 2017' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Hematological Disorders, Immunology and Metabolic Disorders which include indications Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Coronary Artery Disease (CAD) (Ischemic Heart Disease), Critical Limb Ischemia, Non-Small Cell Lung Cancer, Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), Angina (Angina Pectoris), Arteriosclerosis, Chronic Heart Failure, Colorectal Cancer, Dementia, Diabetic Ischemic Foot Ulcers, Diabetic Peripheral Neuropathy, Gastric Cancer, Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Leiomyosarcoma, Liver Cancer, Lymphedema, Metastatic Cancer, Multiple Myeloma (Kahler Disease), Myocardial Infarction, Myocardial Ischemia, Parkinson's Disease, Rheumatoid Arthritis, Solid Tumor and Thromboangiitis obliterans (Buerger disease).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

The report reviews Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics and enlists all their major and minor projects

The report assesses Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Overview 7

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 13

Products under Development by Universities/Institutes 17

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Therapeutics Assessment 19

Assessment by Mechanism of Action 19

Assessment by Route of Administration 21

Assessment by Molecule Type 23

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Companies Involved in Therapeutics Development 25

AnGes MG Inc 25

F-star Biotechnology Ltd 25

Kringle Pharma Inc 26

M3 Biotechnology Inc 26

Minerva Biotechnologies Corp 26

Molecular Partners AG 27

ViroMed Co Ltd 27

Yooyoung Pharm Co Ltd 28

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Drug Profiles 30

beperminogene perplasmid-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

FS-101-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Gene Therapy to Activate HGF for Myocardial Infarction-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Gene Therapy to Antagonize HGF for Rheumatoid Arthritis and Hepatocellular Carcinoma-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

MM-201-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Monoclonal Antibodies to Inhibit Hepatocyte Growth Factor for Metastatic Cancer-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MP-0250-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

NDX-1017-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

NK-4-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

SL-186-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

SL-188-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

VM-202-Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

YYB-101-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Dormant Products 51

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Discontinued Products 53

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF)-Product Development Milestones 54

Featured News & Press Releases 54

Aug 03, 2017: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate VM202 for Non-Healing Diabetic Foot Ulcers 54

Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials 55

Apr 13, 2017: Funding From Alzheimer's Drug Discovery Foundation Advances M3 Biotechnology Toward Human Trials 55

Feb 09, 2017: VM BioPharma Announces Publication of Phase 1/2 Clinical Data of Novel Gene Therapy VM202 in Amyotrophic Lateral Sclerosis (ALS) 56

Sep 20, 2016: F-star to present data on FS-101 at Upcoming AACR Conferences 57

Sep 08, 2016: ViroMed proceeding with the World's first phase III gene therapy clinical trial for diabetic peripheral neuropathy 57

Aug 02, 2016: VM BioPharma Announces Korea Food and Drug Administration Approval of Phase 2 Clinical Trial for Investigational Gene Therapy VM202 in Ischemic Heart Disease 58

Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy 59

Jun 20, 2016: AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia 59

May 18, 2016: VM BioPharma Announces FDA Fast Track Designation Granted for Investigational Gene Therapy VM202 for Patients with Amyotrophic Lateral Sclerosis 60

Apr 15, 2016: AnGes Completes Patient Enrollment for Phase 1/2 Clinical Trials of Gene Therapy with HGF Plasmid in Primary Lymphedema 61

Jan 22, 2016: ViroMed Publishes Results from Critical Limb Ischemia Phase II Clinical Study 61

Jan 08, 2016: Molecular Partners to Conduct Phase II Trial of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Multiple Myeloma 62

Nov 07, 2015: Research Presented at AACR-NCI-EORTC Shows Good Tolerability and Sustained Systemic Exposure of MP0250, a Multi-DARPin Targeting VEGF and HGF, in Patients with Advanced Cancer 63

Oct 27, 2015: First clinical data of multi-DARPin MP0250 to be presented at the AACR-NCI-EORTC oncology conference 64

Appendix 65

Methodology 65

Coverage 65

Secondary Research 65

Primary Research 65

Expert Panel Validation 65

Contact Us 65

Disclaimer 66

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Top 10 Indications, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 19

Number of Products by Stage and Mechanism of Actions, H2 2017 19

Number of Products by Routes of Administration, H2 2017 21

Number of Products by Stage and Routes of Administration, H2 2017 21

Number of Products by Molecule Types, H2 2017 23

Number of Products by Stage and Molecule Types, H2 2017 23

List of Tables

Number of Products under Development by Stage of Development, H2 2017 8

Number of Products under Development by Therapy Areas, H2 2017 9

Number of Products under Development by Indications, H2 2017 10

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12

Number of Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 14

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 16

Number of Products under Investigation by Universities/Institutes, H2 2017 17

Products under Investigation by Universities/Institutes, H2 2017 18

Number of Products by Stage and Mechanism of Actions, H2 2017 20

Number of Products by Stage and Route of Administration, H2 2017 22

Number of Products by Stage and Molecule Type, H2 2017 24

Pipeline by AnGes MG Inc, H2 2017 25

Pipeline by F-star Biotechnology Ltd, H2 2017 26

Pipeline by Kringle Pharma Inc, H2 2017 26

Pipeline by M3 Biotechnology Inc, H2 2017 26

Pipeline by Minerva Biotechnologies Corp, H2 2017 27

Pipeline by Molecular Partners AG, H2 2017 27

Pipeline by ViroMed Co Ltd, H2 2017 28

Pipeline by Yooyoung Pharm Co Ltd, H2 2017 29

Dormant Products, H2 2017 51

Dormant Products, H2 2017 (Contd..1), H2 2017 52

Discontinued Products, H2 2017 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

AnGes MG Inc

F-star Biotechnology Ltd

Kringle Pharma Inc

M3 Biotechnology Inc

Minerva Biotechnologies Corp

Molecular Partners AG

ViroMed Co Ltd

Yooyoung Pharm Co Ltd

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutic Products under Development, Key Players in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Therapeutics, Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline Overview, Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline, Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand

person